Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

GILD

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

GILD

AI Research Report

Powered by Claude

Ready to analyze GILD

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

C+
Stonvex Quant Grade
50.0/ 100
Rank-normalised composite of 6 factors, updated every 60 seconds.
Volume
C+
50 / 100

Today's volume vs prior session average.

Volatility
C+
50 / 100

Absolute daily price move vs peers.

News Flow
C+
50 / 100

24h article count relative to the universe.

Sentiment
C+
50 / 100

AI-classified polarity of recent news.

Dollar Flow
C+
50 / 100

Today's dollar turnover (volume × VWAP).

Relative Strength
C+
50 / 100

Signed daily return vs the rest of the universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Similar stocks

View all Biotech →
MRNA
Moderna
$42.80
+5.29%
LLY
Eli Lilly
$810.50
+2.30%
NVO
Novo Nordisk
—
—
BNTX
BioNTech
—
—
REGN
Regeneron
—
—
VRTX
Vertex Pharma
—
—
Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

whgksdhr1111@naver.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

Gilead Sciences Inc

Gilead Sciences Inc

Biotechnology·NASDAQ NMS - GLOBAL MARKET·US·IPO 1992-01-22
📅 Earnings in 9d (Apr 23)
NASDAQ NMS - GLOBAL MARKETAfter-hours
Gilead Sciences Inc
Biotechnology
$140.28
$1.25 (+0.90%)
After-hrs · vs prev close $139.03
Open
$138.38
Prev close
$139.03
Day range
$137.60 – $140.80
52W range
$93.37 – $157.29
Mkt cap
$172.57B
P/E
20.1
EPS
$6.78
Beta
0.42

Factor Grades

View details →
B
Overall score: 72/100
C+
Valuation
B
Growth
A
Profitability
B+
Momentum
B
Financial Health

Fundamentals

Valuation
Market Cap
$172.57B
P/E (TTM)
20.08S&P avg ~22
P/S (TTM)
5.80S&P avg ~2.8
P/B
6.71S&P avg ~4.5
P/FCF
18.49S&P avg ~26
EPS (TTM)
$6.78
Book/sh
$18.29
Cash/sh
$6.15
Profitability
Gross Margin
78.83%avg ~45%
Operating Margin
34.04%avg ~15%
Net Margin
28.91%avg ~12%
ROE
41.02%avg ~18%
ROA
14.82%avg ~7%
ROI
21.57%
Payout Ratio
110.04%
FCF/sh
—
Growth & Health
Rev Growth YoY
2.40%
Rev Growth 5Y
3.58%
EPS Growth YoY
1903.07%
EPS Growth 5Y
133.64%
Current Ratio
—
Quick Ratio
1.06
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
0.42
52W High
$157.29
52W Low
$93.37
Avg Vol (10D)
5.23M
Avg Vol (3M)
6.94M
Div Yield
2.36%
Div/sh (TTM)
—
Analyst
Buy (39)
Price Performance
5D+0.17%
MTD-0.24%
3M+15.21%
6M+22.41%
YTD+13.27%
1Y+37.11%

Analyst Consensus

Buy
Based on 39 analysts
Period: 2026-04-01
31 Buy (79%)8 Hold (21%)0 Sell (0%)
Rating Distribution
Strong Buy
11
Buy
20
Hold
8
Sell
0
Strong Sell
0
Trend
2026-04
31/8/0
2026-03
30/8/0
2026-02
30/7/0
2026-01
29/8/0
  • Yahoo·11h ago

    1 Profitable Stock for Long-Term Investors and 2 Facing Challenges

    While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".

  • Yahoo·19h ago

    Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing

    SAN FRANCISCO, April 14, 2026--Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing

  • Yahoo·1d ago

    Morgan Stanley Boosts Gilead (GILD) Outlook on Updated Biopharma Models

    Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 13 NASDAQ Stocks with Highest Dividends. On April 10, Morgan Stanley raised the firm’s price recommendation on Gilead Sciences, Inc. (NASDAQ:GILD) to $175 from $171. It kept an Overweight rating on the shares. The firm updated its models across biopharma coverage, reflecting IQVIA trends and intra-quarter updates […]

  • Yahoo·1d ago

    Compugen Highlights AI-Driven IO Pipeline, Key Trial Timelines and Big Pharma Partnerships at Needham Conference

Compugen (NASDAQ:CGEN) outlined progress across its immuno-oncology pipeline and partnerships at the Needham & Company Healthcare Conference, emphasizing the company’s AI-driven target discovery platform and multiple programs now in or approaching clinical readouts. Gil Blum, a senior analyst a

  • Yahoo·1d ago

    Q4 Earnings Highs And Lows: Gilead Sciences (NASDAQ:GILD) Vs The Rest Of The Therapeutics Stocks

    Looking back on therapeutics stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Gilead Sciences (NASDAQ:GILD) and its peers.

  • Finnhub·1d ago

    AHF Slams Gilead for Role in Florida AIDS Drug Crisis

    FORT LAUDERDALE, FL - AIDS Healthcare Foundation is continuing its blistering criticism of Gilead Sciences for its extortionate pricing for its HIV medications and the role that pricing played in...

  • Yahoo·2d ago

    Gilead (GILD), Tempus AI (TEM) Expand Multi-Year Oncology R&D Collaboration

    Gilead Sciences Inc. (NASDAQ:GILD) is one of the 8 Best Quality Stocks to Buy According to Hedge Funds. Gilead Sciences Inc. (NASDAQ:GILD) is one of the best quality stocks to buy according to hedge funds. On April 9, Tempus AI (NASDAQ:TEM) announced an expanded, multi-year collaboration with Gilead Sciences to accelerate Gilead’s oncology research and […]

  • Yahoo·3d ago

    Gilead price target raised to $175 from $171 at Morgan Stanley

    Morgan Stanley raised the firm’s price target on Gilead (GILD) to $175 from $171 and keeps an Overweight rating on the shares. The firm adjusted models among its biopharma coverage for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting from the group.Easter Sale - 70% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Pic

  • View all news →

    • Recent insider activity

    View all →
    • 4FORM 4
      15d ago
    • 4FORM 4
      28d ago
    • 4FORM 4
      28d ago
    • 4FORM 4
      Mar 12
    • 4FORM 4
      Mar 12